TW200612980A - Use of soluble CD26 as inhibitor of angiogenesis and inflammation - Google Patents

Use of soluble CD26 as inhibitor of angiogenesis and inflammation

Info

Publication number
TW200612980A
TW200612980A TW094129079A TW94129079A TW200612980A TW 200612980 A TW200612980 A TW 200612980A TW 094129079 A TW094129079 A TW 094129079A TW 94129079 A TW94129079 A TW 94129079A TW 200612980 A TW200612980 A TW 200612980A
Authority
TW
Taiwan
Prior art keywords
soluble
inflammation
angiogenesis
inhibitor
treatment
Prior art date
Application number
TW094129079A
Other languages
Chinese (zh)
Inventor
ji-wen Zhang
Original Assignee
ji-wen Zhang
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ji-wen Zhang filed Critical ji-wen Zhang
Publication of TW200612980A publication Critical patent/TW200612980A/en

Links

Landscapes

  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention relates to soluble CD26 or a biologically active variant of the soluble CD26 that effectively inhibits angiogenesis and inflammation in a mammalian subject, pharmaceutical compositions comprising the soluble CD26 and the use of soluble CD26 in methods of treatment.
TW094129079A 2004-08-26 2005-08-25 Use of soluble CD26 as inhibitor of angiogenesis and inflammation TW200612980A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US60510304P 2004-08-26 2004-08-26

Publications (1)

Publication Number Publication Date
TW200612980A true TW200612980A (en) 2006-05-01

Family

ID=57807819

Family Applications (1)

Application Number Title Priority Date Filing Date
TW094129079A TW200612980A (en) 2004-08-26 2005-08-25 Use of soluble CD26 as inhibitor of angiogenesis and inflammation

Country Status (1)

Country Link
TW (1) TW200612980A (en)

Similar Documents

Publication Publication Date Title
IL158559A (en) Use of 5-lipoxygenase inhibitors for the preparation of a pharmaceutical composition for treating acne
MY143795A (en) Tetrahydropyridoindole derivatives
TW200728285A (en) Diacylindazole derivatives as inhibitors of lipases and phospholipases
MX2007007885A (en) Orally disintegrating pharmaceutical compositions with sensory cue agents.
EA200601776A1 (en) METADONIC COMPOSITIONS OF LOCAL ACTION AND METHODS OF THEIR APPLICATION
HK1118579A1 (en) Adamts13-comprising compositions having thrombolytic activity
MY143407A (en) Indazole derivatives as inhibitors of hormone sensitive lipase
MY142329A (en) Novel benzo-fused heteroaryl sulfamide derivatives useful as anticonvulsant agents.
TW200621268A (en) Antimicrobial copolymers and uses thereof
WO2004030611A3 (en) Non-nucleoside reverse transcriptase inhibitors
WO2002091999A3 (en) Treatment for wounds
ATE456369T1 (en) FLIBANSERIN FOR THE TREATMENT OF URINARY INCONTINENCE AND ASSOCIATED DISEASES
EP1962843A4 (en) Use of parp-1 inhibitors
GB0421900D0 (en) Inhibition of tumour cell migration
TW200716091A (en) New therapeutic combinations for the treatment or prevention of psychotic disorders
TW200730513A (en) Carbamoylbenzotriazole derivatives as inhibitors of lipases and phospholipases
TW200727903A (en) Stable pharmaceutical compositions of 5, 10 methylenetetrahydrofolate
HK1112721A1 (en) Tissue disruption treatment and composition for use thereof
TW200730190A (en) New combination to treat liver fibrosis
RS54185B1 (en) Use of 24-norudca
TNSN07203A1 (en) Pharmaceutical compositions for the treatment of cellulite
MY139425A (en) Pharmaceutical composition comprising 2,4-dichlorobenzyl alcohol and amylmetacresol
WO2006026172A3 (en) Use of soluble cd26 as inhibitor of angiogenesis and inflammation
IL185096A0 (en) Polymer compositions and their use in the production of active or effective ingredient compositions
HK1111924A1 (en) Depigmenting or brightening cosmetic composition comprising at least one oxazolin as an active ingredient